FL-AMGTA
The Additive Manufacturer Green Trade Association (AMGTA), a global trade organization created to promote the environmental benefits of additive manufacturing (AM), announced today that it had named Sherri Monroe its new Executive Director, effective immediately. Ms. Monroe’s extensive non-profit work includes roles as the Regional Chief Development Officer and Executive Director of the American Red Cross, as well as the Program Marketing and Community Engagement Manager of the American Cancer Society. In addition, Ms. Monroe has worked successfully in the for-profit innovation space, most recently in support of Siemens Energy in Orlando, Florida.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220606005789/en/
“I am thrilled to be joining the AMGTA at this critical point in its development,” said Ms. Monroe. “Additive manufacturing has the potential to be transformational in how we sustainably manufacture, and it is our role at the AMGTA to help unlock this potential through rigorous research and industry outreach.”
“Sherri’s proven leadership in both the non-profit and for-profit worlds is the perfect background for our Executive Director role,” said Brian Neff, the AMGTA’s Board Chair. “I am looking forward to working with her as she continues the remarkable growth of our organization.”
The AMGTA is expected to announce the findings of its first commissioned life cycle analysis, which involved an aircraft engine bracket, later this summer.
About AMGTA
The AMGTA was launched in November 2019 to promote the environmental benefits of additive manufacturing (AM) over traditional methods of manufacturing. The AMGTA is a non-commercial, unaffiliated organization open to any additive manufacturer or industry stakeholder worldwide that meets certain criteria relating to sustainability of production or process. For more information, please contact Sherri Monroe, at +1 954.308.0888, or visit www.amgta.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005789/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vodafone Spain and Twilio Partner to Offer Secure and Interactive RCS Messaging to Businesses in Spain23.10.2025 10:00:00 CEST | Press release
81% of consumers prefer RCS over SMS, and 71% of businesses plan to adopt it in the next year. Twilio, the customer engagement platform that powers personalised, real-time experiences for today's leading brands, has announced an extended partnership with Vodafone Spain, one of the country's leading telecommunications operators. This will enable Spanish businesses to access Rich Communication Services (RCS) messaging, revolutionising the way they interact with their customers through rich, interactive and secure communications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023623745/en/ Vodafone Spain has relied on Twilio's global expertise to accelerate the adoption of this next-generation messaging solution, positioning it as the new standard for business communication in the Spanish market. A much needed evolution for mobile communication In a world where personalisation and trust are essential for brand to consumer re
AGC Biologics Partners with Rarity PBC to Advance Life-Saving Gene Therapy for "Bubble Baby Disease"23.10.2025 09:00:00 CEST | Press release
Collaboration will leverage AGC Biologics’ commercial manufacturing experience and proven platforms to seek regulatory approval for a therapy treating the rare immunodeficiency disorder, ADA-SCID. AGC Biologics, your friendly CDMO expert, today announced an agreement with Rarity PBC to provide comprehensive development and Good Manufacturing Practice (GMP) manufacturing for Rarity's gene therapy, RDP-101, for Adenosine Deaminase Severe Combined Immunodeficiency Disorder. If approved by the U.S. Food and Drug Administration, RDP-101 would be the first gene therapy available for commercial use to reverse ADA-SCID in patients within the United States. ADA-SCID is a rare, life-threatening inherited condition that severely compromises the immune system, leaving infants vulnerable to frequent and severe infections. For every million babies born worldwide, it is estimated that between one and five will have this condition. The ADA-SCID disorder caused by an Adenosine Deaminase deficiency is f
TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation23.10.2025 08:01:00 CEST | Press release
Imagine a traveler’s perfect day planning itself, rerouting around a rainstorm, prompting a café to add staff before the lunch rush, suggesting a quiet gallery when crowds swell. This is the promise of Agentic Tourism, an AI-powered operating model introduced in a new white paper by TOURISE and Globant, a digitally native company that helps organizations thrive in a digital and AI-powered future, with strategic contribution from Kearney. The report, titled Tourism’s AI Takeover: Reinventing Travel through Agentic Tourism, presents a practical framework for transforming the tourism experience making it more seamless, intelligent, and emotionally resonant. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022347041/en/ TOURISE and Globant Unveil New White Paper on Agentic AI in Tourism In 2024, tourism generated 10.9 trillion dollars, nearly 10 percent of global GDP, and is projected to reach 16.5 trillion dollars by 2035. AI
Bureau Veritas:Robust and Consistent Revenue Performance Delivered in Q3 2025; FY 2025 Outlook Reaffirmed23.10.2025 07:30:00 CEST | Press release
Bureau Veritas (BOURSE:BVI): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022995674/en/ Hinda Gharbi, CEO Bureau Veritas Q3 2025 Key figures1 › Revenue of EUR 1,583.7 million, up 2.3% year-on-year and up 6.3% organically › A very strong organic growth from Marine & Offshore at 16.2%; solid recovery of Buildings & Infrastructure at 7.1% organically; strong organic growth maintained for both Industry and Certification, at 6.9% and 5.9% respectively, against challenging comparables; moderate organic growth for Consumer Products Services at 3.5% and Agri-Food & Commodities at 2.5% › Positive scope effect of 0.8%, from the accelerated pace of bolt-on acquisitions (+3.1% contribution) realized, net of disposals (-2.3% contribution) › Negative currency impact of 4.8%, resulting from the euro’s appreciation against most currencies Q3 2025 Highlights › Continued progress in implementing the LEAP I 28 strategy, delivering results
Bureau Veritas Accelerating Its LEAP | 28 Strategy With Two Signed Agreements for Acquisitions in Buildings & Infrastructure and Renewables23.10.2025 07:20:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification (TIC) services, announces that it has signed agreements to acquire two companies in Europe, reinforcing its leading position and expanding into high-potential markets: Sólida in the renewables sector, and London Building Control in the Buildings & Infrastructure market. These agreements underscore Bureau Veritas’ commitment to growth within its LEAP I 28 strategy, increasing capability, reach, and technical expertise across growth markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022071543/en/ Hinda Gharbi, CEO Bureau Veritas Sólida is a top-tier provider of Owner’s Engineering, Technical Advisory, and Project Management services for renewable energy projects and electrical infrastructure. It acts as a trusted technical partner for leading developers, utilities, EPC contractors, investment funds and financial institutions. The Company has demo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom